Participant flow15

How many started, completed or left each group, period by period.

1 to 15 of 15

Period	Milestone	Group	Participants
Overall Study	STARTED	Baloxavir	612
Overall Study	STARTED	Placebo	310
Overall Study	STARTED	Oseltamivir	514
Overall Study	Received Study Drug	Baloxavir	610
Overall Study	Received Study Drug	Placebo	309
Overall Study	Received Study Drug	Oseltamivir	513
Overall Study	Intention to Treat Infected Population	Baloxavir	456
Overall Study	Intention to Treat Infected Population	Placebo	231
Overall Study	Intention to Treat Infected Population	Oseltamivir	377
Overall Study	COMPLETED	Baloxavir	578
Overall Study	COMPLETED	Placebo	290
Overall Study	COMPLETED	Oseltamivir	498
Overall Study	NOT COMPLETED	Baloxavir	34
Overall Study	NOT COMPLETED	Placebo	20
Overall Study	NOT COMPLETED	Oseltamivir	16

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT02954354/flow